Page last updated: 2024-10-31

midazolam and Cerebral Cholesterinosis

midazolam has been researched along with Cerebral Cholesterinosis in 1 studies

Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Szalat, A1
Gershkovich, P1
Ben-Ari, A1
Shaish, A1
Liberman, Y1
Boutboul, E1
Gotkine, M1
Hoffman, A1
Harats, D1
Leitersdorf, E1
Meiner, V1

Trials

1 trial available for midazolam and Cerebral Cholesterinosis

ArticleYear
Rifampicin-induced CYP3A4 activation in CTX patients cannot replace chenodeoxycholic acid treatment.
    Biochimica et biophysica acta, 2007, Volume: 1771, Issue:7

    Topics: Adult; Antibiotics, Antitubercular; Bile Acids and Salts; Chenodeoxycholic Acid; Cholestanol; Cytoch

2007